Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer
The emerging CDH6-directed antibody-drug conjugate raludotatug deruxtecan had a manageable safety profile, generated pharmacokinetic activity, and produced early evidence of clinical response in patients with heavily pretreated, platinum-resistant ovarian cancer.
Kathleenn Moore Daiichi Sankyo Speaker For Research To Practice Clinical Research Oklahoma City Research To Practice
Source: onclive.com